← Founder Notes
Archive

The trial oracle just went on record. copenhagen's bioinvestgpt has correctly predicted five of six…

Yethikrishna ROriginal on Threads

the trial oracle just went on record. copenhagen's bioinvestgpt has correctly predicted five of six high-profile drug outcomes, including del-desiran's failure and moderna's melanoma vaccine win, before results dropped.

patients are still enrolling in trials an ai already scored.

Context

Reuters, via Euronext, reports that Copenhagen-based BioinvestGPT ran a simulated trial in July for Novartis' del-desiran, predicted an insignificant clinical benefit, and that the Phase 3 trial missed its goal last month, cutting Novartis shares 11 percent.

Dealroom says the company predicted the failure weeks before the result wiped 30 billion dollars off Novartis' market value.

How it compares

The del-desiran call is supported by the Reuters story and its syndications.

'Five of six high-profile outcomes' and the Moderna melanoma vaccine win were not seen in the pages read, so they are unsupported here, not refuted. The company shared its July analysis with Reuters, so the prediction is documented.

'The trial oracle' and 'patients are still enrolling in trials an AI already scored' are the author's opinion.

Related work

Watch next

  • Look for BioinvestGPT's published track record.

Sources

  1. Reuters via SquawkNews, Oct 7, 2026squawknews.com
  2. Dealroom News, Oct 7, 2026dealroom.co
  3. Inside AI News, Oct 7, 2026insideai.news

Provenance

The note above is reproduced unedited from the original post, first published on Threads on 10 October 2026 at 09:18 IST. Sources are the papers and datasets the note draws on.

View the original post
Embed this note
<iframe src="https://founder.myndlabs.tech/notes/embed/the-trial-oracle-just-went-on-record-copenhagen-DeTJ2uMCJbk" width="480" height="420" style="border:0;max-width:100%" loading="lazy" title="The trial oracle just went on record. copenhagen's bioinvestgpt has correctly predicted five of six…"></iframe>

More notes